While PI3K/Akt/mTOR inhibitors have been effective treating other hematological malignancies, such as chronic lymphoblastic leukemia (CLL) and follicular lymphoma (FL), in AML, the clinical potential of PI3K/Akt/mTOR inhibitors has not yet been fully elucidated [29,30,31]. Here, PIK3CA is linked to acute myeloid leukemia.